[Skip to Content]
[Skip to Content Landing]
Editorial
December 13, 2016

Artificial Intelligence With Deep Learning Technology Looks Into Diabetic Retinopathy Screening

Author Affiliations
  • 1Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
  • 2Duke-NUS Medical School, National University of Singapore, Singapore
  • 3Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
  • 4Editor, JAMA Ophthalmology
JAMA. 2016;316(22):2366-2367. doi:10.1001/jama.2016.17563

Diabetic retinopathy is a leading cause of vision loss in the United States and globally, particularly among working-aged individuals. Diabetic retinopathy meets all the criteria for screening: first, the condition (diabetic retinopathy) is an important public health care problem; second, the epidemiology and natural history of the condition, including development from asymptomatic latent to severe disease, are adequately understood; third, the screening test (retinal photography) is simple, safe, validated, and acceptable; and fourth, an effective treatment (intravitreous injections of anti–vascular endothelial growth factor or laser therapy for severe diabetic retinopathy or diabetic macular edema [DME]) is available for patients identified through early detection. Diabetic retinopathy screening has long been recommended by the American Diabetes Association, the American Academy of Ophthalmology, and many international societies.

×